ARCH BIOPARTNERS INC (ARCH.CA) Forecast, Price Target & Analyst Ratings
TSX-V:ARCH • CA03938C1041
0.77 CAD
-0.03 (-3.75%)
Last: Mar 9, 2026, 07:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARCH BIOPARTNERS INC (ARCH.CA).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateMay 28, 2026
ChartMill Buy Consensus
45.71%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of CA$0.77 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
ARCH.CA was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about ARCH.CA.
In the previous month the buy percentage consensus was at a similar level.
ARCH.CA was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 28, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.984M 105.62% | 2.122M 6.97% | 275.9K -87.00% | -100.00% | 85.703M | 181.73M 112.05% | 290.15M 59.66% | ||
| EBITDA YoY % growth | N/A 51.22% | N/A -25.00% | N/A -140.00% | -16.521M -36.31% | -17.037M -3.12% | 64.225M 476.97% | 155.09M 141.48% | 256.9M 65.65% | |
| EBIT YoY % growth | -2.996M -177.43% | -3.558M -18.74% | -1.242M 65.10% | -11.979M -864.74% | -2.604M 78.26% | 64.019M 2,558.33% | 154.88M 141.93% | 256.08M 65.34% | |
| Operating Margin | -151.05% | -167.67% | -450.05% | N/A | N/A | 74.70% | 85.23% | 88.26% | |
| EPS YoY % growth | -0.05 -71.62% | N/A -35.96% | N/A | -0.16 -131.43% | -0.04 75.00% | N/A | N/A | N/A |
All data in CAD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in CAD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
248.78%
Revenue Next 5 Year
170.06%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
89.45%
EBIT Next 5 Year
84.18%
ARCH BIOPARTNERS INC / ARCH.CA Forecast FAQ
What is the next earnings date for ARCH stock?
ARCH BIOPARTNERS INC (ARCH.CA) will report earnings on 2026-05-28.
What is the consensus rating for ARCH BIOPARTNERS INC (ARCH.CA) stock?
The consensus rating for ARCH BIOPARTNERS INC (ARCH.CA) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.